PharmaCorp Rx Inc. PCRX.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 19.83M | 17.42M | 14.97M | 12.60M | 9.92M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 19.83M | 17.42M | 14.97M | 12.60M | 9.92M |
| Cost of Revenue | 11.99M | 10.57M | 9.03M | 7.59M | 6.03M |
| Gross Profit | 7.84M | 6.85M | 5.95M | 5.01M | 3.89M |
| SG&A Expenses | 7.87M | 7.14M | 6.17M | 4.63M | 4.08M |
| Depreciation & Amortization | 904.60K | 799.80K | 673.50K | 565.10K | 459.30K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.77M | 18.51M | 15.87M | 12.78M | 10.56M |
| Operating Income | -942.50K | -1.10M | -898.70K | -186.30K | -641.90K |
| Income Before Tax | -549.30K | -777.80K | -611.90K | 217.10K | -188.30K |
| Income Tax Expenses | 199.90K | 337.80K | 419.10K | 99.10K | 113.40K |
| Earnings from Continuing Operations | -0.75 | -1.12 | -1.03 | 0.12 | -0.30 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -114.40K | -47.50K | -42.40K | 5.10K | 19.70K |
| Net Income | -863.60K | -1.16M | -1.07M | 123.00K | -282.10K |
| EBIT | -942.50K | -1.10M | -898.70K | -186.30K | -641.90K |
| EBITDA | -149.60K | -379.70K | -277.30K | 326.20K | -216.80K |
| EPS Basic | -0.01 | -0.01 | -0.01 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 614.13M | 557.34M | 500.55M | 469.43M | 465.29M |
| Average Diluted Shares Outstanding | 632.67M | 566.67M | 508.42M | 477.29M | 473.15M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |